Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: Genetic factors

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 6, 2005, Pages 1394-1401

  Morimoto, Libby M ^a   Newcomb, Polly A ^a,b,c   White, Emily ^a   Bigler, Jeannette ^a   Potter, John D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 20444412679     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0694     Document Type: Article

References (100)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
2. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
3. Collett-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996;25:591-614.
4. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
5. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
6. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001;85:991-6.
7. Djavan B, Waldert M, Seitz C, Marberger M. Insulin-like growth factors and prostate cancer. World J Urol 2001;19:225-33.
8. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001;85:1695-9.
9. Kaaks R, Toniolo P, Akhmedkhanov A, et al. C-Peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
10. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
11. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9:345-9.
12. Yu H, Jin F, Shu XO, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:705-12.
13. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1566-73.
14. Bruning PF, Van Doorn J, Bonfrer JM, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62:266-70.
15. Hankinson SE, Willet WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998;351:1393-96.
16. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998;9:570-3.
17. Li BD, Khosravi MJ, Berkel HJ, et al. Free insulin-like growth factor-1 and breast cancer risk. Int J Cancer 2001;91:736-9.
18. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-1 and breast cancer. Int J Cancer 2000;88:828-32.
19. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
20. London SJ, Yuan JM, Travlos GS, et al. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002;94:749-54.
21. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.
22. Garnero P, Sornay-Rendu E, Delmas PD. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000;355:898-9.
23. Goke B, Fehmann HC. Insulin and insulin-like growth factor-I: their role as risk factors in the development of diabetic cardiovascular disease. Diabetes Res Clin Pract 1996;30:93-106.
24. Clemmons DR. Role of peptide growth factors in development of macrovascular complications of diabetes. Diabetes Care 1991;14:153-6.
25. Boonen S, Mohan S, Dequeker J, et al. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 1999;14:2150-8.
26. Barrett-Connor E, Goodman-vGruen D. Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo Study. J Bone Miner Res 1998;13:1343-9.
27. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000;36:1224-8.
28. Harris TB, Kiel D, Roubenoff R, et al. Association of insulin-like growth factor-I with body composition, weight history, and past health behaviors in the very old: the Framingham Heart Study. J Am Geriatr Soc 1997;45:133-9.
29. Donahue LR, Hunter SJ, Sherblom AP, Rosen C. Age-related changes in serum insulin-like growth factor-binding proteins in women. J Clin Endocrinol Metab 1990;71:575-9.
30. Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:862-7.
31. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997;145:970-6.
32. Lukanova A, Toniolo P, Akhmedkhanov A, et al. A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev 2001;10:443-52.
33. Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ. Lifestyle determinants of serum insulin-like growth-factor-1 (IGF-1), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 2003;14:65-74.
34. Chang S, Wu X, Yu H, Spitz MR. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomarkers Prev 2002;11:758-66.
35. Platz EA, Pollak MN, Rimm EB, et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107-10.
36. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-84.
37. Voskuil DR, de Mesquita HB, Kaaks R, et al. Determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1-3 in premenopausal women: physical activity and anthropometry (Netherlands). Cancer Causes Control 2001;12:951-8.
38. Teramukai S, Rohan T, Eguchi H, Oka T, Shinchi K, Kono S. Anthropometric and behavioral correlates of insulin-like growth factor I and insulin-like growth factor binding protein3 in middle-aged Japanese men. Am J Epidemiol 2002;156:344-8.
39. Devine A, Rosen C, Mohan S, Baylink D, Prince RL. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women. Am J Clin Nutr 1998;68:200-6.
40. Giovannucci E, Pollak M, Liu Y, et al. Nutritional predictors of insulin-like growth factor 1 and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9.
41. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 1999;17:3291-8.
42. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:852-61.
43. Kao PC, Matheny AP, Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 1994;78:310-2.
44. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFPB-1, and IGFBP-3. J Clin Invest 98:2612-5.
45. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-80.
46. Zou T, Fleisher AS, Kong D, et al. Sequence alterations of insulin-like growth factor binding protein 3 in neoplastic and normal gastrointestinal tissues. Cancer Res 1998;58:4802-4.
47. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
48. Jernstrom H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001;72:144-54.
49. Newcomb PA, Haile R, Anton-Culver H, et al. The Colorectal Cancer Family Registry: 1998-2002. Cancer Epidemiol Biomarkers Prev 2002;11:1222-3s.
50. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71 -80.
51. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, Lamberts SW. A polymorphism in the IGF-1 gene influences the age-related decline in circulating total IGF-1 levels. Eur J Endocrinol 2003;148:171-5.
52. Allen NE, Davey GK, Key TJ, Zhang S, Narod SA. Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-1 gene. Cancer Epidemiol Biomarkers Prev 2002;11:319-20.
53. Kim JG, Roh KR, Lee JY. The relationship among serum insulin-like growth factor-I, insulin-like growth factor-I gene polymorphism, and bone mineral density in postmenopausal women in Korea. Am J Obstet Gynecol 2002;186:345-50.
54. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 health children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-52.
55. Probst-Hensch NM, Wang H, Goh VHH, Seow A, Lee H-P, Yu MC. Determinants of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarkers Prev 2003;12:739-46.
56. Schoen RE, Schragin J, Weissfeld JL, et al. Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. Cancer Epidemiol Biomarkers Prev 2002;11:581-6.
57. McCarthy TL, Ji C, Shu H, et al. 17β-Estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures, J Biol Chem 1997;272:18132-9.
58. Miyao M, Hosoi T, Inoue S, et al. Polymorphism of insulin-like growth factor I gene and bone mineral density. Calcif Tissue Int 1998;63:306-11.
59. Takacs I, Koller DL, Peacock M, et al. Sibling pair linkage and association studies between bone mineral density and the insulin-like growth factor I gene locus. J Clin Endocrinol Metab 1999;84:4467-71.
60. Sun G, Gagnon J, Chagnon YC, et al. Association and linkage between an insulin-like growth factor-1 gene polymorphism and fat free mass in the HERITAGE family study. Int J Obes Relat Metab Disord 1999;23:929-35.
61. Frayling TM, Hattersley AT, McCarthy A, et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes 2002;51:2313-6.
62. Rasmussen SK, Lautier C, Hansen L, et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:1606-10.
63. Vaessen N, Janssen JA, Heutink P, et al. Association between genetic variation in the gene for insulin-like growth factor-1 and low birthweight. Lancet 2002;359:1036-7.
64. Jansen M, van Schaik FM, Ricker AT, et al. Sequence of cDNA encoding human insulin-like growth factor 1 precursor. Nature 1983;306:609-11.
65. Tobin G, Yee D, Brunner N, Rotwein PA. A novel human insulin-like growth factor 1 messenger RNA is expression in normal and tumor cells. Mol Endocrinol 1990;4:1914-20.
66. Smith PJ, Spurrell EL, Coakley J, et al. An exonic splicing enhancer in human IGF-1 pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor. Endocrinology 2002;143:146-54.
67. West CA, Arnett TR, Farrow SM. Expression of insulin-like growth factor 1 (IGF-1) mRNA variants in rat bone. Bone 1996;19:41-6.
68. Shemer J, Adamo ML, Roberts CT Jr, LeRoith D. Tissue-specific transcription start site usage in the leader exons of the rat insulin-like growth factor-I gene: evidence for differential regulation in the developing kidney. Endocrinology 1992;131:2793-9.
69. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591-614.
70. Jansen E, Steenbergh PH, LeRoith D, Roberts CT Jr, Sussenbach JS. Identification of multiple transcription start sites in the human insulin-like growth factor-I gene. Mol Cell Endocrinol 1991;78:115-25.
71. Mittanck DW, Kim SW, Rotwein P. Essential promoter elements are located within the 5́ untranslated region of human insulin-like growth factor-1 exon 1. Mol Cell Endocrinol 1997;126:153-63.
72. Roy RN, Cecutti A, Gerulath AH, Steinberg WM, Bhavnani BR. Endometrial transcripts of human insulin-like growth factors arise by differential promoter usage. Mol Cell Endocrinol 1997;135:11-9.
73. Pell JM, Saunders JC, Gilmour RS. Differential regulation of transcription initiation from insulin-like growth factor-1 (IGF-1) leader exons and of tissue IGF-1 expression in response to changed growth hormone and nutritional status in sheep. Endocrinology 1993;132:1797-807.
74. Zhang J, Chrysis D, Underwood LE. Reduction of hepatic insulin-like growth factor 1 (IGF-1) messenger ribonucleic acid (mRNA) during fasting is associated with diminished splicing of IGF-1 pre-mRNA and decreased stability of cytoplasmic IGF-1 mRNA. Endocrinology 1998;139:4523-30.
75. Zhang J, Whitehead REJ, Underwood LE. Effect of fasting on insulin-like growth factor (IGF)-1A and IGF-1B messenger ribonucleic acids and prehormones in rat liver. Endocrinology 1997;138:3112-8.
76. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-B-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995;270:13589-92.
77. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor B2-induced growth inhibition in human breast cancer cells. Cancer Res 1996;56:1545-50.
78. Huynh H, Yang XF, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016-21.
79. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1a,25-dihydroxyvitamin D3 growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319-24.
80. Vorwerk P, Yamanaka Y, Spagnoli A, Oh Y, Rosenfeld RG. Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine. J Clin Endocrinol Metab 1998;83:1392-5.
81. Imai Y, Moralez A, Andag U, Clarke JB, Busby WH Jr, Clemmons DR. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J Biol Chem 2000;275:18188-94.
82. Buckway CK, Wilson EM, Ahlsen M, Bang P, Oh Y, Rosenfeld RG. Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J Clin Endocrinol Metab 2001;86:4943-50.
83. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: influence of serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003;107:60-4.
84. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998;279:563-6.
85. Kelly PJ, Eisman JA, Stuart MC, Pocock NA, Sambrook PN, Gwinn TH. Somatomedin-C, physical fitness, and bone density. J Clin Endocrinol Metab 1990;70:718-23.
86. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1994;41:351-7.
87. Janssen JA, Stolk RP, Pols HA, Grobbee DE, de Jong FH, Lamberts SW. GF-1, total IGF-1, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. Clin Endocrinol, 1998;48:471-8.
88. Signorello LB, Kuper H, Lagiou P, et al. Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 2000;9:173-8.
89. Colletti RB, Copeland KC, Devlin JT, Roberts JD, McAuliffe TL. Effect of obesity on plasma insulin-like growth factor-1 in cancer patients. Int J Obes 1991;15:523-7.
90. Veldhuis JD, Liem AY, South S, et al. Differential impact of age, sex, steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1995;80:3209-22.
91. Vestergaard P, Hermann AP, Orskov H, Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J Clin Endocrinol Metab 1999;84:2286-90.
92. Heald A, Selby PL, White A, Gibson JM. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 2000;183:593-600.
93. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor-1, and GH-binding protein in postmenopausal women. J Clin Endocrinol 1999;72:374-81.
94. Cano A, Castelo-Branco C, Tarin JJ. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releaseing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertil Steril 1999;71:261-7.
95. Cardim HJ, Lopes CM, Giannella-Neta D, da Fonseca AM, Pinotti JA. The insulin-like growth factor-I system and hormone replacement therapy. Fertil Steril 2001;75:282-7.
96. Duschek EJ, de Valk-de Roo GW, Gooren LJ, Netelenbos C. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3:2-year, doubleblind, placebo-controlled study. Fertil Steril 2004;82:384-90.
97. Kam GYW, Leung K-C, Baxter RC, Ho KKY. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 2000;85:1918-22.
98. Martin MB, Stoica A. Insulin-like growth factor-1 and estrogen interactions in breast cancer. J Nutr 2002;132:3799-801S.
99. Rochefort H. Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur J Cancer 1994;30A:1583-6.
100. Binoux M, Roghani M, Hossenlopp P, Hardouin S, Gourmelen M. Molecular forms of human IGF binding proteins: Pnhysiological implications. Acta Endocrinol (Cophen), 1991;124:41-7.